PDF下载 ( 2168 KB)
Chinese guidelines on the management of liver cirrhosis
-
摘要:
<正>1前言肝硬化是各种慢性肝病进展至以肝脏弥漫性纤维化、假小叶形成、肝内外血管增殖为特征的病理阶段,代偿期无明显临床症状,失代偿期以门静脉高压和肝功能严重损伤为特征,患者常因并发腹水、消化道出血、脓毒症、肝性脑病、肝肾综合征和癌变等导致多脏器功能衰竭而死亡。美国肝病学会(American Association for the Study of Liver
-
Key words:
- liver cirrhosis /
- diagnosis /
- therapeutics /
- practice guidelines as topic
-
[1] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460. [2] European Association for the Study of the Live. EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J]. J Hepatol,2010,53(3):397-417. [3] RUNYON BA,AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis2012[J]. Hepatology,2013,57(4):1651-1653. [4] PELLICORO A,RAMACHANDRAN P,IREDALE JP,et al. Liver fibrosis and repair:Immune regulation of wound healing in a solid organ[J]. Nat Rev Immunol,2014,14(3):181-194. [5] YANG N,SHI JJ,WU FP,et al. Caffeic acid phenethyl ester up-regulates antioxidant levels in hepatic stellate cell line T6via an Nrf2-mediated mitogen activated protein kinases pathway[J]. World J Gastroenterol,2017,23(7):1203-1214. [6] Chinese Society of Hepatology,Chinese Medical Association,XU X,DUAN Z,et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis[J]. Hepatol Int,2019,13(1):1-21. [7] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Endoscopy,Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J].J Clin Hepatol,2016,32(2):203-219.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．临床肝胆病杂志，2016,32(2):203-219. [8] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病学分会．肝硬化肝性脑病诊疗指南[J]．临床肝胆病杂志，2018,34(10):2076-2089. [9] BERZIGOTTI A,ABRALDES JG. Impact of obesity and insulin-resistance on cirrhosis and portal hypertension[J]. Gastroenterol Hepatol,2013,36(8):527-533. [10] BERZIGOTTI A,ALBILLOS A,VILLANUEVA C,et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity:The SportDiet study[J]. Hepatology,2017,65(4):1293-1305. [11] PARKER R,KIM SJ,IM GY,et al. Obesity in acute alcoholic hepatitis increases morbidity and mortality[J]. EBio Medicine,2019,45:511-518. [12] MONTANO-LOZA AJ,ANGULO P,MEZA-JUNCO J,et al.Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis[J]. J Cachexia Sarcopenia Muscle,2016,7(2):126-135. [13] HARA N,IWASA M,SUGIMOTO R,et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis[J]. Intern Med,2016,55(8):863-870. [14] ABBAS M,ABBAS Z. Serum cholinesterase:A predictive biomarker of hepatic reserves in chronic hepatitis D[J]. World J Hepatol,2017,9(22):967-972. [15] DUFOUR DR,LOTT JA,NOLTE FS,et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening,diagnosis,and monitoring[J]. Clin Chem,2000,46(12):2050-2068. [16] ANTHONY PP,ISHAK KG,NAYAK NC,et al. The morphology of cirrhosis:Definition,nomenclature,and classification[J]. Bull World Health Organ,1977,55(4):521-540. [17] MALINCHOC M,KAMATH PS,GORDON FD,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology,2000,31(4):864-871. [18] WU SL,ZHENG YX,TIAN ZW,et al. Scoring systems for prediction of mortality in decompensated liver cirrhosis:A metaanalysis of test accuracy[J]. World J Clin Cases,2018,6(15):995-1006. [19] MAJLESARA A,GOLRIZ M,HAFEZI M,et al. Indocyanine green fluorescence imaging in hepatobiliary surgery[J]. Photodiagnosis Photodyn Ther,2017,17:208-215. [20] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988. [21] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769. [22] Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology,Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis:A2018 update[J]. Chin J Hepatol,2019,27(3):182-191.(in Chinese)中国肝炎防治基金会．瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]．中华肝脏病杂志，2019,27(3):182-191. [23] HE YB,BAI L,JIANG Y,et al. Application of a three-dimensional reconstruction technique in liver autotransplantation for end-stage hepatic alveolar echinococcosis[J]. J Gastrointest Surg,2015,19(8):1457-1465. [24] CAI W,FAN Y,HU H,et al. Postoperative liver volume was accurately predicted by a medical image three dimensional visualization system in hepatectomy for liver cancer[J]. Surg Oncol,2017,26(2):188-194. [25] LO RC,KIM H. Histopathological evaluation of liver fibrosis and cirrhosis regression[J]. Clin Mol Hepatol,2017,23(4):302-307. [26] KIM SU,OH HJ,WANLESS IR,et al. The laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis[J].J Hepatol,2012,57(3):556-563. [27] DENIZ K,OZCAN S,OZBAKIR O,et al. Regression of steatohepatitis-related cirrhosis[J]. Semin Liver Dis,2015,35(2):199-202. [28] BEDOSSA P,POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group[J]. Hepatology,1996,24(2):289-293. [29] NAGULA S,JAIN D,GROSZMANN RJ,et al. Histologicalhemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis[J]. J Hepatol,2006,44(1):111-117. [30] KUMAR M,SAKHUJA P,KUMAR A,et al. Histological subclassification of cirrhosis based on histological-haemodynamic correlation[J]. Aliment Pharmacol Ther,2008,27(9):771-779. [31] Chinese Portal Hypertension Diagnosis and Monitoring Study Group(CHESS); Minimally Invasive Intervention Collaborative Group,Chinese Society of Gastroenterology; Emergency Intervention Committee,Chinese College of Interventionalists,et al. Consensus on clinical application of hepatic venous pressure gradient in China(2018)[J]. J Clin Hepatol,2018,34(12):2526-2536.(in Chinese)中国门静脉高压诊断与监测研究组(CHESS)，中华医学会消化病学分会微创介入协作组，中国医师协会介入医师分会急诊介入专业委员会，等．中国肝静脉压力梯度临床应用专家共识(2018版)[J]．临床肝胆病杂志，2018,34(12):2526-2536. [32] QI X,AN W,LIU F,et al. Virtual hepatic venous pressure gradient with CT angiography(CHESS 1601):A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology,2019,290(2):370-377. [33] LIU F,NING Z,LIU Y,et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis(CHESS1701):A prospective multicenter study[J]. EBio Medicine,2018,36:151-158. [34] MORGAN MY,MADDEN AM,SOULSBY CT,et al. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis[J]. Hepatology,2006,44(4):823-835. [35] Chinese Society of Hepatology,Chinese Society of Gastroenterology,Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol,2019,35(6):1222-1230.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会．终末期肝病临床营养指南[J]．临床肝胆病杂志，2019,35(6):1222-1230. [36] WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[M]. Geneva:World Health Organization,2015. [37] BUTI M,FUNG S,GANE E,et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years[J]. Hepatol Int,2015,9(2):243-250. [38] KONG Y,SUN Y,ZHOU J,et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Viral Hepat,2019,26(5):576-585. [39] RUSSO FP,ZANETTO A,CAMPELLO E,et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals[J]. Liver Int,2018,38(12):2210-2218. [40] GRGUREVIC I,BOZIN T,MADIR A. Hepatitis C is now curable,but what happens with cirrhosis and portal hypertension afterwards?[J]. Clin Exp Hepatol,2017,3(4):181-186. [41] MARCELLIN P,ASSELAH T. Long-term therapy for chronic hepatitis B:Hepatitis B virus DNA suppression leading to cirrhosis reversal[J]. J Gastroenterol Hepatol,2013,28(6):912-923. [42] ARVANITI V,D’AMICO G,FEDE G,et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology,2010,139(4):1246-1256,1256. e1241-1245. [43] SULTAN S,PAUWELS A,POUPON R,et al. Chylous ascites in cirrhosis. Retrospective study of 20 cases[J]. Gastroenterol Clin Biol,1990,14(11):842-847. [44] RECTOR WG Jr. Spontaneous chylous ascites of cirrhosis[J].J Clin Gastroenterol,1984,6(4):369-372. [45] STEINEMANN DC,DINDO D,CLAVIEN PA,et al. Atraumatic chylous ascites:Systematic review on symptoms and causes[J]. J Am Coll Surg,2011,212(5):899-905. e891-894. [46] BADILLO R,ROCKEY DC. Hepatic hydrothorax:Clinical features,management,and outcomes in 77 patients and review of the literature[J]. Medicine(Baltimore),2014,93(3):135-142. [47] GARBUZENKO DV,AREFYEV NO. Hepatic hydrothorax:An update and review of the literature[J]. World J Hepatol,2017,9(31):1197-1204. [48] REIBERGER T,PUSPOK A,SCHODER M,et al. Austrian consensus guidelines on the management and treatment of portal hypertension(Billroth III)[J]. Wien Klin Wochenschr,2017,129(Suppl 3):135-158. [49] SMITH E,TEKOLA B,PATRIE J,et al. Clinical characterization of gastric antral vascular ectasia:A potential manifestation of the metabolic syndrome[J]. Am J Med,2016,129(12):1329. e19-1329. e23. [50] TSAI CJ,SANAKA MR,MENON KV,et al. Balloon-assisted enteroscopy in portal hypertensive enteropathy[J]. Hepatogastroenterology,2014,61(134):1635-1641. [51] DE PALMA GD,REGA M,MASONE S,et al. Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension:A capsule endoscopy study[J]. Gastrointest Endosc,2005,62(4):529-534. [52] BESA C,CRUZ JP,HUETE A,et al. Portal biliopathy:A multitechnique imaging approach[J]. Abdom Imaging,2012,37(1):83-90. [53] NARDONE R,HOLLER Y,STORTI M,et al. Spinal cord involvement in patients with cirrhosis[J]. World J Gastroenterol,2014,20(10):2578-2585. [54] RENJEN PN,KHANNA L,RASTOGI R,et al. Acquired hepatocerebral degeneration[J]. BMJ Case Rep, 2013. pii:bcr2013009387. [55] BURKHARD PR,DELAVELLE J,DU PASQUIER R,et al. Chronic parkinsonism associated with cirrhosis:A distinct subset of acquired hepatocerebral degeneration[J]. Arch Neurol,2003,60(4):521-528. [56] LEWIS MB,MACQUILLAN G,BAMFORD JM,et al. Delayed myelopathic presentation of the acquired hepatocerebral degeneration syndrome[J]. Neurology,2000,54(4):1011. [57] BURGOS A,BERMEJO PE,CALLEJA JL,et al. Acquired chronic hepatocerebral degeneration due to cirrhosis from non-alcoholic steatohepatitis[J]. Rev Esp Enferm Dig,2009,101(11):806-811. [58] ANGELI P,GARCIA-TSAO G,NADIM MK,et al. News in pathophysiology,definition and classification of hepatorenal syndrome:A step beyond the International Club of Ascites(ICA)consensus document[J]. J Hepatol,2019,71(4):811-822. [59] ROSI S,PIANO S,FRIGO AC,et al. New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients:Can we use an imputed value of serum creatinine?[J]. Liver Int,2015,35(9):2108-2114. [60] SHAH N,DHAR D,EL ZAHRAA MOHAMMED F,et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression[J]. J Hepatol,2012,56(5):1047-1053. [61] ADEBAYO D,MORABITO V,DAVENPORT A,et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy[J]. Kidney Int,2015,87(3):509-515. [62] BUCSICS T,KRONES E. Renal dysfunction in cirrhosis:Acute kidney injury and the hepatorenal syndrome[J]. Gastroenterol Rep(Oxf),2017,5(2):127-137. [63] WONG F,O’LEARY JG,REDDY KR,et al. Acute kidney injury in cirrhosis:Baseline serum creatinine predicts patient outcomes[J]. Am J Gastroenterol,2017,112(7):1103-1110. [64] ANGELI P,GINES P,WONG F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol,2015,62(4):968-974. [65] PATIDAR KR,KANG L,BAJAJ JS,et al. Fractional excretion of urea:A simple tool for the differential diagnosis of acute kidney injury in cirrhosis[J]. Hepatology,2018,68(1):224-233. [66] WANG WJ,SONG Q,DING HG. The clinical characteristics and risk factors for acute kidney injury in patients with cirrhosis[J].Chin J Intern Med,2018,57(12):912-916.(in Chinese)王文娟，宋琦，丁惠国．肝硬化患者急性肾损伤的临床特点及危险因素分析[J]．中华内科杂志，2018,57(12):912-916. [67] WEHMEYER MH,HEUER AJ,BENTEN D,et al. High rate of cardiac abnormalities in a postmortem analysis of patients suffering from liver cirrhosis[J]. J Clin Gastroenterol,2015,49(10):866-872. [68] MøLLER S,HOVE JD,DIXEN U,et al. New insights into cirrhotic cardiomyopathy[J]. Int J Cardiol,2013,167(4):1101-1108. [69] MEHTA G,GUSTOT T,MOOKERJEE RP,et al. Inflammation and portal hypertension-the undiscovered country[J]. J Hepatol,2014,61(1):155-163. [70] NAGUEH SF,SMISETH OA,APPLETON CP,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography:An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging,2016,17(12):1321-1360. [71] KWON HM,HWANG GS. Cardiovascular dysfunction and liver transplantation[J]. Korean J Anesthesiol,2018,71(2):85-91. [72] ZHAO J,QI X,HOU F,et al. Prevalence,risk factors and in-hospital outcomes of QTc interval prolongation in liver cirrhosis[J]. Am J Med Sci,2016,352(3):285-295. [73] VANNUCCI A,RATHOR R,VACHHARAJANI N,et al. Atrial fibrillation in patients undergoing liver transplantation-a single-center experience[J]. Transplant Proc,2014,46(5):1432-1437. [74] KROWKA MJ,FALLON MB,KAWUT SM,et al. International Liver Transplant Society practice guidelines:Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension[J]. Transplantation,2016,100(7):1440-1452. [75] SARIN SK,PHILIPS CA,KAMATH PS,et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis[J]. Gastroenterology,2016,151(4):574-577,e3. [76] European Association for the Study of the Liver. EASL clinical practice guidelines:Vascular diseases of the liver[J]. J Hepatol,2016,64(1):179-202. [77] de FRANCHIS R,Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752. [78] BASILI S,PASTORI D,RAPARELLI V,et al. Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis:Insights for the clinician[J]. Therap Adv Gastroenterol,2018,11:1756284818793561. [79] ENGLESBE MJ,SCHAUBEL DE,CAI S,et al. Portal vein thrombosis and liver transplant survival benefit[J]. Liver Transpl,2010,16(8):999-1005. [80] CHEN H,TURON F,HERNANDEZ-GEA V,et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation[J]. Liver Transpl,2016,22(3):352-365. [81] THOMPSON A. Portal vein thrombosis-a primer for the general physician[J]. Clin Med(Lond),2017,17(5):479. [82] DUPUIS M,SPAHR L,GIOSTRA E,et al. Portal vein thrombosis in patients with cirrhosis[J]. Rev Med Suisse,2017,13(572):1470-1473. [83] von KOCKRITZ L,de GOTTARDI A,TREBICKA J,et al. Portal vein thrombosis in patients with cirrhosis[J]. Gastroenterol Rep(Oxf),2017,5(2):148-156. [84] TO UK,GARCIA-TSAO G. PRO:Patients with advanced cirrhosis and portal vein thrombosis should receive anticoagulation[J]. Clin Liver Dis(Hoboken),2018,12(3):74-79. [85] ZHOU J,SUN HC,WANG Z,et al. Guidelines for diagnosis and treatment of primary liver cancer in China(2017 Edition)[J]. Liver Cancer,2018,7(3):235-260. [86] GONZALEZ-CALVIN JL,GALLEGO-ROJO F,FERNANDEZ-PEREZ R,et al. Osteoporosis,mineral metabolism,and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis[J]. J Clin Endocrinol Metab,2004,89(9):4325-4330. [87] GOUBRAIM R,KABBAJ N,SALIHOUN M,et al. Metabolic bone disease in viral cirrhosis:A prospective study[J]. ISRN Hepatol,2013,2013:276563. [88] RASZEJA-WYSZOMIRSKA J,MIAZGOWSKI T. Osteoporosis in primary biliary cirrhosis of the liver[J]. Prz Gastroenterol,2014,9(2):82-87. [89] ENGELKE K,LIBANATI C,LIU Y,et al. Quantitative computed tomography(QCT)of the forearm using general purpose spiral whole-body CT scanners:Accuracy,precision and comparison with dual-energy X-ray absorptiometry(DXA)[J]. Bone,2009,45(1):110-118. [90] KIM G,KANG SH,KIM MY,et al. Prognostic value of sarcopenia in patients with liver cirrhosis:A systematic review and meta-analysis[J]. PLo S One, 2017, 12(10):e0186990. [91] BELARMINO G,TORRINHAS RS,HEYMSFIELD SB,et al.Sarcopenia in liver cirrhosis:The role of computed tomography scan in the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry[J].Eur J Gastroenterol Hepatol,2015,27(10):1228. [92] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2019 update[J]. J Clin Hepatol,2019.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2019更新版)[J]．临床肝胆病杂志，2019. [93] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2019 update[J]. J Clin Hepatol,2019.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019更新版)[J]．临床肝胆病杂志，2019. [94] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):939-946.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．酒精性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):939-946. [95] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957. [96] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J]. J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．自身免疫性肝炎诊断和治疗共识(2015)[J]．临床肝胆病杂志，2016,32(1):9-22. [97] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary sclerosing cholangitis(2015)[J]. J Clin Hepatol,2016,32(1):23-31.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性硬化性胆管炎诊断和治疗专家共识(2015)[J]．临床肝胆病杂志，2016,32(1):23-31. [98] KAMISAWA T,NAKAZAWA T,TAZUMA S,et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis[J]. J Hepatobiliary Pancreat Sci,2019,26(1):9-42. [99] European Association for Study of Liver. EASL clinical practice guidelines:Wilson’s disease[J]. J Hepatol,2012,56(3):671-685. [100] ROBERTS EA,SCHILSKY ML,American Association for Study of Liver Diseases(AASLD). Diagnosis and treatment of Wilson disease:An update[J]. Hepatology,2008,47(6):2089-2111. [101] POWELL LW,SECKINGTON RC,DEUGNIER Y. Haemochromatosis[J]. Lancet,2016,388(10045):706-716. [102] HUANG A,LIANG QS,SUN Y,et al. Research progress in the diagnosis and treatment of chronic drug-induced liver injury[J]. Infect Dis Info,2018,31(2):105-107.(in Chinese)黄昂，梁庆升，孙颖，等．慢性药物性肝损伤的诊治研究进展[J]．传染病信息，2018,31(2):105-107. [103] COLLEY DG,BUSTINDUY AL,SECOR WE,et al. Human schistosomiasis[J]. Lancet,2014,383(9936):2253-2264. [104] QIAN MB,UTZINGER J,KEISER J,et al. Clonorchiasis[J].Lancet,2016,387(10020):800-810. [105] Chinese Society of Infectious Diseases,Chinese Medical Association,Expert Committee for Prevention and Management of Liver Inflammation. Consensus statement by the expert committee for prevention and management of liver inflammation in China[J]. Chin J Hepatol,2014,22(2):94-103.(in Chinese)中华医学会感染病学分会，肝脏炎症及其防治专家共识专家委员会．肝脏炎症及其防治专家共识[J]．中华肝脏病杂志，2014,22(2):94-103. [106] ZHANG L,SCHUPPAN D. Traditional Chinese Medicine(TCM)for fibrotic liver disease:Hope and hype[J]. J Hepatol,2014,61(1):166-168. [107] NAN YM,KONG LB. Advances in diagnosis and treatment of liver cirrhosis with integrated traditional Chinese and Western medicine[J]. Chin J Hepatol,2018,26(5):328-331.(in Chinese)南月敏，孔令波．肝硬化的中西医结合诊治进展[J]．中华肝脏病杂志，2018,26(5):328-331. [108] TIAN YL,ZHU XY,YIN WW,et al. Supplemental Fuzhenghuayu capsule therapy for improving liver fibrosis markers in patients with chronic hepatitis B following unsatisfactory outcome of nucleos(t)ide analogue monotherapy[J]. Chin J Hepatol,2013,21(7):514-518.(in Chinese)田玉岭，朱晓云，殷卫卫，等．扶正化瘀胶囊序贯联合核苷(酸)类似物对慢性乙型肝炎肝纤维化指标的影响[J]．中华肝脏病杂志，2013,21(7):514-518. [109] JIANG YF,MA J,HE B,et al. The therapeutic effect of Anluohuaxian capsule combined with adefovir dipivoxil on patients with chronic hepatitis B and influence on hepatic histology[J].Chin J Hepatol,2012,20(5):344-347.(in Chinese)蒋永芳，马静，贺波，等．阿德福韦酯联合安络化纤丸治疗慢性乙型肝炎的疗效[J]．中华肝脏病杂志，2012,20(5):344-347. [110] YANG NH,YUAN GS,ZHOU YC,et al. Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis:96-week efficacy analyses[J].J South Med Univ,2016,36(6):775-779.(in Chinese)杨年欢，袁国盛，周宇辰，等．恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化96周的临床疗效[J]．南方医科大学学报，2016,36(6):775-779. [111] XIAO DH,GU J,CAI H,et al. A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis[J]. Chin J Hepatol,2014,22(8):594-599.(in Chinese)肖定洪，顾杰，蔡虹，等．扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J]．中华肝脏病杂志，2014,22(8):594-599. [112] WANG L,LU W,GAO YH,et al. Effect of Anluohuaxianwan on the expression of matrix metalloproteinases and their inhibitors in rat liver with fibrosis[J]. Chin J Hepatol,2019,27(4):267-273.(in Chinese)王林，卢玮，高玉华，等．安络化纤丸对肝纤维化大鼠组织基质金属蛋白酶及其抑制物表达的影响[J]．中华肝脏病杂志，2019,27(4):267-273. [113] LIZAOLA B,BONDER A,TRIVEDI HD,et al. Review article:The diagnostic approach and current management of chylous ascites[J]. Aliment Pharmacol Ther,2017,46(9):816-824. [114] BHARDWAJ R,VAZIRI H,GAUTAM A,et al. Chylous ascites:A review of pathogenesis,diagnosis and treatment[J].J Clin Transl Hepatol,2018,6(1):105-113. [115] LI Y,DING HG. Current diagnosis and treatment of chylous ascites[J]. J Prac Hepatol,2018,21(5):665-668.(in Chinese)李越，丁惠国．乳糜性腹水诊治现状[J]．实用肝脏病杂志，2018,21(5):665-668. [116] BERZIGOTTI A,MAGALOTTI D,COCCI C,et al. Octreotide in the outpatient therapy of cirrhotic chylous ascites:A case report[J]. Dig Liver Dis,2006,38(2):138-142. [117] ZHOU DX,ZHOU HB,WANG Q,et al The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis[J]. Dig Dis Sci,2009,54(8):1783-1788. [118] LIU KL,SUN YG,XIA S,et al. Analysis of clinical features of34 cases with liver cirrhosis complicated with chylous ascites[J]. Chin J Dig,2014,34(2):96-99.(in Chinese)刘揆亮，孙宇光，夏松，等．肝硬化合并乳糜性腹水34例临床特点分析[J]．中华消化杂志，2014,34(2):96-99. [119] HU LJ,WANG LJ,JIAN YC,et al. Efficacy of octreotide treatment for chylous ascites after liver cirrhosis:A case report and literature review[J]. J Clin Hepatol,28(8):624-625.(in Chinese)胡丽娟，王丽晶，简易成，等．奥曲肽治愈肝硬化乳糜性腹水1例并文献复习[J]．临床肝胆病杂志，2012,28(8):624-625. [120] LEONG RW,HOUSE AK,JEFFREY GP. Chylous ascites caused by portal vein thrombosis treated with octreotide[J]. J Gastroenterol Hepatol,2003,18(10):1211-1213. [121] TSAUO J,SHIN JH,HAN K,et al. Transjugular intrahepatic portosystemic shunt for the treatment of chylothorax and chylous ascites in cirrhosis:A case report and systematic review of the literature[J]. J Vasc Interv Radiol,2016,27(1):112-116. [122] URRUNAGA NH,SINGAL AG,CUTHBERT JA,et al. Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis[J]. J Hepatol,2013,58(6):1113-1118. [123] PACHE I,BILODEAU M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease[J]. Aliment Pharmacol Ther,2005,21(5):525-529. [124] PEREIRA SP,ROWBOTHAM D,FITT S,et al. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone(vitamin K1)in severe acute liver disease[J].J Hepatol,2005,42(3):365-370. [125] LEE EW,SHAHROUKI P,ALANIS L,et al. Management options for gastric variceal hemorrhage[J]. JAMA Surg,2019,154(6):540-548. [126] HOSKING SW,KENNEDY HJ,SEDDON I,et al. The role of propranolol in congestive gastropathy of portal hypertension[J]. Hepatology,1987,7(3):437-441. [127] PEREZ-AYUSO RM,PIQUE JM,BOSCH J,et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis[J]. Lancet,1991,337(8755):1431-1434. [128] ZHOU Y,QIAO L,WU J,et al. Comparison of the efficacy of octreotide,vasopressin,and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy:A controlled study[J]. J Gastroenterol Hepatol,2002,17(9):973-979. [129] PATWARDHAN VR,CARDENAS A. Review article:The management of portal hypertensive gastropathy and gastric antral vascular ectasia in cirrhosis[J]. Aliment Pharmacol Ther,2014,40(4):354-362. [130] KAMATH PS,LACERDA M,AHLQUIST DA,et al. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis[J]. Gastroenterology,2000,118(5):905-911. [131] URRUNAGA NH,ROCKEY DC. Portal hypertensive gastropathy and colopathy[J]. Clin Liver Dis,2014,18(2):389-406. [132] Society of Infectious Diseases,Chinese Medical Association.Expert consensus on diagnosis and treatment of end-stage liver disease complicated infection[J]. J Clin Hepatol,2018,34(9):1862-1872.(in Chinese)中华医学会感染病学分会．终末期肝病合并感染诊治专家共识[J]．临床肝胆病杂志，2018,34(9):1862-1872. [133] RHODES A,EVANS LE,ALHAZZANI W,et al. Surviving sepsis campaign:International guidelines for management of sepsis and septic shock:2016[J]. Crit Care Med,2017,45(3):486-552. [134] DHIMAN RK,THUMBURU KK,VERMA N,et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy:A systematic review&network meta-analysis[J].Clin Gastroenterol Hepatol,2019.[Epub ahead of print] [135] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association; Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol,2019,35(1):38-44.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组．肝衰竭诊治指南(2018年版)[J]．临床肝胆病杂志，2019,35(1):38-44. [136] WANG H,LIU A,BO W,et al. Terlipressin in the treatment of hepatorenal syndrome:A systematic review and meta-analysis[J]. Medicine(Baltimore),2018,97(16):e0431. [137] ZHAN GQ,LI F,LI RG,et al. Efficacy of terlipressin therapy for refractory ascites in cirrhosis and type-2 hepatorenal syndrome[J]. J Clin Hepatol,2015,31(8):1287-1290.(in Chinese)占国清，李芳，李儒贵，等．特利加压素治疗肝硬化顽固性腹水合并Ⅱ型肝肾综合征的疗效观察[J]．临床肝胆病杂志，2015,31(8):1287-1290. [138] BOYER TD,SANYAL AJ,WONG F,et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1[J]. Gastroenterology,2016,150(7):1579-1589. e2. [139] ISRAELSEN M,KRAG A,ALLEGRETTI AS,et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome[J]. Cochrane Database Syst Rev,2017,9:CD011532. [140] CAVALLIN M,KAMATH PS,MERLI M,et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:A randomized trial[J]. Hepatology,2015,62(2):567-574. [141] TANG W,JIANG MD,XU H,et al. The study on plasma exchange combined with noradrenalin in the treatment of severe hepatitis with typeⅡhepatorenal syndrome[J]. Beijing Med J,2011,33(9):713-716.(in Chinese)唐文，蒋明德，徐辉，等．血浆置换联合去甲肾上腺素治疗重型肝炎合并Ⅱ型肝肾综合征的临床疗效分析[J]．北京医学，2011,33(9):713-716. [142] DONG QH,GUO LM,LIU JY,et al. Albumin dialysis combined with noradrenalin in the treatment of severe hepatitis with type 1 hepatorenal syndrome[J]. Chin J Gastroenterol Hepatol,2009,18(9):852-854.(in Chinese)董庆华，郭利民，刘景院，等．白蛋白透析联合去甲肾上腺素治疗重型肝炎Ⅰ型肝肾综合征临床研究[J]．胃肠病学和肝病学杂志，2009,18(9):852-854. [143] ROSSLE M,GERBES AL. TIPS for the treatment of refractory ascites,hepatorenal syndrome and hepatic hydrothorax:A critical update[J]. Gut,2010,59(7):988-1000. [144] LEE YB,LEE JH. Cirrhotic cardiomyopathy:An independent prognostic factor for cirrhotic patients[J]. Clin Mol Hepatol,2018,24(4):372-373. [145] LIU H,JAYAKUMAR S,TRABOULSI M,et al. Cirrhotic cardiomyopathy:Implications for liver transplantation[J]. Liver Transpl,2017,23(6):826-835. [146] SOULAIDOPOULOS S,CHOLONGITAS E,GIANNAKOULAS G,et al. Review article:Update on current and emergent data on hepatopulmonary syndrome[J]. World J Gastroenterol,2018,24(12):1285-1298. [147] IQBAL S,SMITH KA,KHUNGAR V. Hepatopulmonary syndrome and portopulmonary hypertension:Implications for liver transplantation[J]. Clin Chest Med,2017,38(4):785-795. [148] FUKUSHIMA KY,YATSUHASHI H,KINOSHITA A,et al. Two cases of hepatopulmonary syndrome with improved liver function following long-term oxygen therapy[J]. J Gastroenterol,2007,42(2):176-180. [149] LOFFREDO L,PASTORI D,FARCOMENI A,et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis:A systematic review and Meta-analysis[J]. Gastroenterology,2017,153(2):480-487. e1. [150] CUI SB,SHU RH,YAN SP,et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Eur J Gastroenterol Hepatol,2015,27(8):914-919. [151] PRIYANKA P,KUPEC JT,KRAFFT M,et al. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis[J]. Int J Hepatol,2018,2018:8432781. [152] XI J,LIU XJ,CHEN JY. Research progress in anticoagulant therapy of liver cirrhosis complicated with portal vein thrombosis[J]. Med Recapitulate,2019,25(2):335-340.(in Chinese)席娟，刘熙钰，陈嘉屿．肝硬化并发门静脉血栓的抗凝治疗研究进展[J]．医学综述，2019,25(2):335-340. [153] KOCONIS KG,SINGH H,SOARES G. Partial splenic embolization in the treatment of patients with portal hypertension:A review of the english language literature[J]. J Vasc Interv Radiol,2007,18(4):463-481. [154] LI XQ,WANG YB,GONG JP,et al. Partial splenic embolization in treatment of hypersplenism secondary to liver cirrhosis:Meta-analysis[J]. Chin J Interv Imaging Ther,2018,15(3):160-166.(in Chinese)李学强，王运兵，龚建平，等．部分脾动脉栓塞治疗肝硬化继发脾功能亢进的Meta分析[J]．中国介入影像与治疗学，2018,15(3):160-166. [155] BONE HG,HOSKING D,DEVOGELAER JP,et al. Ten years’experience with alendronate for osteoporosis in postmenopausal women[J]. N Engl J Med,2004,350(12):1189-1199. [156] BLACK DM,REID IR,BOONEN S,et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis:A randomized extension to the HORIZON-Pivotal Fracture Trial(PFT)[J]. J Bone Miner Res,2012,27(2):243-254. [157] ZEIN CO,JORGENSEN RA,CLARKE B,et al. Alendronate improves bone mineral density in primary biliary cirrhosis:A randomized placebo-controlled trial[J]. Hepatology,2005,42(4):762-771. [158] GUANABENS N,MONEGAL A,CERDA D,et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis[J]. Hepatology,2013,58(6):2070-2078. [159] WU XQ. Influence of psychological intervention on medical compliance and life quality of patients with hepatocirrhosis[J]. Chin J Prac Nurs,2011,27(8):3-4.(in Chinese)巫香球．心理护理干预对肝硬化患者遵医行为和生存质量的影响[J]．中国实用护理杂志，2011,27(8):3-4. -
本文二维码
计量
- 文章访问数: 3308
- HTML全文浏览量: 96
- PDF下载量: 2083
- 被引次数: 0
下载:
